Table 2.

Design and mortality of the in vivo experiment

Group no.a	No. of animalsb	MTA (treatment 1)			GEM (treatment 2)			Mortality (N [%])d
		Dosage (mg/kg)	Administration route	Treatment periodc	Dosage (mg/kg)	Administration route	Treatment periodc	Tox	Tu	Op
1A	14	–	–	–	–	–	–	0	1 (7)	1 (7)
1 B	14	–	–	–	–	–	–	0	1 (7)	0 8
2	17	–	–	–	50	HACEe	8	0	0	4 (24)
3	13	–	–	–		IVf		0	0	2 (15)
4	13	30	i.v.c)	1–5	–	–	–	0	3 (23)	0
5	10	60						0	0	0
6	14	90						0	0	0
7	14	30			50	HACEf)	8	0	0	2 (14)
8	14	60						1 (7)	0	2 (14)
9	12	90						1 (8)	0	0
10	13	30	PVCEd)	1	–	–	–	0	0	1 (8)
11	11	60						0	0	0
12	13	90						0	0	0
13	14	30			50	HACEf)	8	0	0	4 (29)
14	13	60						2 (15)	0	0
15	11	90						0	0	1 (9)
	Total 210							4 (2)	5 (2)	17 (8)
									26 (12)

^aThe two subgroups of the control groups reflect two subsequent experimental periods: Period A comprises groups 4–6 and 10–12; period B comprises groups 2, 3, 7–9, and 13–15

^b4×10⁶ CC531-lac-Z cells were implanted intraportally to male WAG-Rij rats (day 1)

^cTreatment period (days) of drug administration after tumor cell implantation (day 1)

^dAnimals that died within the experimental period (days 1–22) because of drug toxicity (Tox), tumor growth (Tu), or operation (Op)

^eHepatic artery chemoembolization: Combined administration of starch microspheres (30 mg/kg) and the respective drug dosage

^fIntravenous injection

^gPortal vein chemoembolization: Combined administration of starch microspheres (30 mg/kg) and the respective drug dosage